Here’s what keeps commercial analytics teams up at night: you’re trying to size a market opportunity for a specialty drug launch, and your traditional epidemiology-based projections say one thing, while your analog forecasts from similar products suggest something entirely different. Meanwhile, your market access team needs precise patient population estimates for payer negotiations, and your VP is asking for confidence intervals you simply can’t provide with top-down sales audit data.
The pharmaceutical industry has relied on the same playbook for decades—global sales tracking systems, bottom-up epidemiological modeling, and analog-based forecasting. These methods aren’t wrong, exactly. They’re just… incomplete. And in today’s competitive landscape, incomplete means you’re leaving millions on the table or worse, overcommitting resources to opportunities that don’t exist.
What’s changing? Aggregated insurance claims datasets are fundamentally transforming how pharma companies approach market sizing and opportunity assessment. We’re talking about billions of de-identified, adjudicated prescription and medical claims that capture what’s actually happening in clinical practice—not what we think might happen based on trial data or projected market share assumptions.
Why Traditional Pharma Market Sizing Falls Short
The uncomfortable truth about traditional market sizing is this: it’s built on assumptions layered upon assumptions. You start with epidemiology (how many patients have the condition?), multiply by treatment rates (how many get treated?), factor in market share projections (how many will choose our drug?), and hope your pricing assumptions hold. Each step introduces error, and by the time you reach your final market potential figure, you’re often 40% off—sometimes more.
I’ve seen this play out dozens of times. A biotech company sizes the Continental European market for a rare disease therapy at €650M based on published prevalence rates and treatment paradigms from clinical guidelines. They launch, and actual utilization comes in at €370M. What happened? The epidemiology data didn’t account for diagnostic challenges in community practice. The treatment rate assumptions came from academic centers, not real-world settings. And the market share projections failed to anticipate payer restrictions that weren’t visible in traditional data sources.
Top-down approaches using sales audits have their own blindspots. Sure, prescription tracking systems capture volumes moving through retail and specialty pharmacies, but they tell you what’s being dispensed—not necessarily what patients are actually taking, how long they stay on therapy, or what happens when they switch. For commercial teams trying to understand competitive dynamics or forecast LOE impact, that gap between dispensing and adherence matters enormously.
And here’s the thing about analog forecasting: it assumes your product will behave like previous launches in the category. But every drug is different—different efficacy profiles, different safety concerns, different payer coverage patterns. Without real-world utilization data to ground your assumptions, you’re essentially making educated guesses with very expensive consequences.
The Real-World Data Revolution in Market Sizing
Insurance claims data changes the entire equation. Instead of projecting from epidemiology or extrapolating from analogues, you’re working with actual, adjudicated records of what physicians prescribed, what pharmacies dispensed, what patients filled, and what payers covered. Real-world evidence has emerged as a critical tool for understanding pharmaceutical markets beyond controlled clinical trial settings.
Let me be specific about what we’re talking about here. Aggregated claims datasets from specialized providers combine de-identified records from millions of covered lives across commercial, public insurance, and supplementary health insurance populations. These aren’t samples or projections—they’re comprehensive longitudinal records capturing diagnoses (ICD-10 codes), procedures (procedure classification codes), prescriptions (ATC classification with product identifiers), and healthcare utilization patterns over time.
The scale is remarkable. Robust claims datasets can include 200+ million patient-years of data, representing 30-40% of the insured population across multiple European markets. That’s sufficient statistical power to analyze even rare disease populations with confidence, segment by geography or payer type, and track treatment patterns across the full patient journey from diagnosis through multiple lines of therapy.
What makes claims data particularly valuable for pharma market sizing is the closed-loop nature of the information. When a claim is adjudicated, you know the prescription was actually filled (not just written), you know what the patient paid versus what insurance covered, and you can track whether they refilled on schedule or discontinued therapy. Healthcare claims data provides actionable insights that traditional sales audits simply cannot capture.
How Aggregated Insurance Claims Data Transforms Market Opportunity Assessment
The practical applications for commercial analytics teams are extensive. Start with the most fundamental question: how big is the opportunity? With claims data, you’re not estimating prevalence from population studies—you’re counting actual diagnosed patients in the database, adjusting for coverage rates, and projecting to the total insured population. The precision difference is substantial.
For a specialty oncology drug, traditional epidemiology might suggest 58,000 eligible patients across Continental Europe based on published incidence rates and biomarker prevalence. Claims data reveals that only 36,000 patients are actually diagnosed with the specific biomarker-positive subtype in real-world practice, and of those, only 23,000 receive any systemic therapy within 90 days of diagnosis. That’s the addressable market—not the theoretical one.
But market sizing is just the beginning. Opportunity assessment requires understanding the competitive landscape, treatment patterns, and unmet needs. Here’s where claims data really shines. You can see exactly which therapies patients receive in first-line, second-line, and subsequent settings. You can calculate time-to-treatment initiation, duration of therapy, discontinuation rates, and switching patterns. You can identify gaps—patient populations that aren’t receiving guideline-recommended care, or clinical scenarios where existing therapies are being used off-label because nothing better exists.
Consider a real-world scenario: a pharmaceutical company developing a novel therapy for Type 2 diabetes wants to assess the market opportunity beyond just prevalent patient counts. Claims analysis reveals several critical insights that epidemiology alone wouldn’t show. First, while 15% of diagnosed T2D patients might be eligible based on clinical characteristics, only 8% actually receive injectable therapies in the first three years after diagnosis due to physician prescribing patterns and patient preferences. Second, among patients who do start injectables, adherence drops to 40% by month six, creating a retention opportunity for better-tolerated options. Third, there’s significant regional variation—uptake is 3x higher in endocrinology practices versus primary care, suggesting the need for targeted launch strategies.
This level of granularity fundamentally changes how you think about market potential. You’re not just sizing the total addressable market (TAM)—you’re understanding the serviceable addressable market (SAM) and the serviceable obtainable market (SOM) with data-driven precision.
Refining Pharma Forecasting with Claims-Based Market Intelligence
Forecasting accuracy improves dramatically when you ground your models in real-world utilization data rather than assumptions. Integration of real-world data accelerates drug development and enables more accurate commercial planning throughout the product lifecycle.
Traditional analog forecasting takes a previous drug launch (or composite of similar launches) and adjusts for differences in efficacy, safety, pricing, and market conditions. The problem? Those adjustments are largely subjective. How much should you adjust the uptake curve because your drug has a once-weekly dosing advantage? What discount factor should you apply because competitors have established relationships with key prescribers? Without empirical data on how these factors actually influence prescribing behavior, you’re guessing.
Claims data provides the evidence base for these adjustments. You can analyze historical launches in the same therapeutic area and quantify exactly how dosing frequency, administration route, safety profile, or formulary position impacted adoption rates. You can track how quickly first prescriptions turned into repeat prescriptions, how long patients stayed on therapy before switching, and what patient characteristics predicted persistence.
For new product planning teams, this transforms portfolio decisions. Instead of relying on qualitative assessments of “high” versus “medium” commercial potential, you can model specific scenarios with confidence intervals. If your Phase III trial shows a 15% efficacy improvement over standard of care, claims data on similar therapeutic advances in the category can tell you what that typically translates to in terms of market share and revenue—not what consultants project, but what actually happened with comparable products.
The forecasting benefits extend to loss-of-exclusivity planning as well. Generic entry doesn’t follow a standard erosion curve—it varies enormously by therapeutic class, formulary dynamics, and prescriber behavior. Claims analysis of previous LOE events in your category reveals the actual timeline of brand-to-generic conversion, identifies patient segments that stay on brand longer (often due to specific insurance coverage or physician preferences), and quantifies the true revenue impact of biosimilar competition.
Enabling Precise Market Access Strategies with Real-World Utilization Data
Market access negotiations live or die on evidence. Payers want to know: how many of our members will use this drug? What’s the budget impact? What’s the real-world effectiveness compared to existing options? Real-world data supports coverage and payment decisions by providing payers with the evidence they need to make informed formulary placement choices.
Claims data provides the ammunition your HEOR team needs for these discussions. You can show payers exactly how many of their current members fit your indicated population based on diagnosis codes and prior treatment history. You can model budget impact using actual utilization patterns from commercial populations rather than theoretical projections. And critically, you can demonstrate real-world effectiveness through retrospective outcomes analysis—showing that in everyday practice (not just controlled trials), patients who received treatments similar to yours achieved better glycemic control, fewer hospitalizations, or improved quality of life metrics.
The specificity matters enormously. A payer isn’t impressed by pan-European prevalence statistics—they want to know about their population. Claims data lets you segment by plan type, geography, and member characteristics to provide payer-specific analyses. For a regional health plan covering 400,000 lives, you can estimate that approximately 3,200 members would be eligible for your therapy based on diagnostic patterns in comparable populations, and project first-year uptake between 480-640 members based on observed adoption curves for similar specialty drugs in that region.
This precision reduces the uncertainty that drives payers toward restrictive coverage policies. When you can demonstrate with empirical data that your budget impact estimates are conservative and grounded in real utilization patterns, you’re far more likely to secure favorable formulary placement without burdensome prior authorization requirements.
Supporting Commercial Execution with Claims-Derived Market Intelligence
Beyond strategic planning, aggregated claims data enables tactical commercial execution. Brand marketing teams need to identify high-opportunity prescribers—not just high-volume physicians, but those whose current prescribing patterns suggest openness to your product profile. Claims analysis reveals which specialists are early adopters of new therapies, which primary care physicians actively manage complex patients who might benefit from your drug, and which institutions have patient populations matching your target indication.
The geographic intelligence is particularly valuable. Claims data can pinpoint metropolitan areas or healthcare systems with high prevalence of your target condition, helping you prioritize territory assignments and allocate sales resources efficiently. If you’re launching a specialty drug for a rare genetic disorder, claims analysis might reveal that 40% of diagnosed patients in your database are concentrated in just 15 metropolitan areas, with three academic medical centers accounting for 25% of all treatments. That changes your entire go-to-market strategy.
Sales operations teams use claims-derived insights to set realistic quotas and forecast territory potential. Instead of dividing the regional opportunity equally or using crude population-based adjustments, you’re assigning targets based on actual patient populations, competitive intensity, and historical prescriber behavior in each geography. The result? More accurate incentive compensation, better resource allocation, and improved sales force morale because quotas actually reflect territory potential.
Overcoming Data Quality Challenges in Claims-Based Analysis
Now, aggregated insurance claims data isn’t perfect—no real-world data source is. There are legitimate challenges that sophisticated analytics teams need to address. Statistical considerations for real-world evidence in drug development include addressing data quality and completeness issues inherent in claims datasets.
First, claims data is billing-focused, not research-focused. The ICD-10 diagnosis codes were designed for reimbursement, not clinical precision. A claim for “Type 2 diabetes mellitus with hyperglycemia” (E11.65) doesn’t tell you the patient’s HbA1c level, duration of disease, or comorbidity severity. Lab results, vital signs, and patient-reported outcomes aren’t captured in standard claims. For questions requiring that level of clinical granularity, you need linked claims-EHR datasets or supplemental data sources.
Second, patient continuity can be challenging. Closed claims datasets (from specific payers) provide complete records but patients may disenroll if they change jobs or insurance, creating right-censoring issues for longitudinal analyses. Open claims datasets (aggregated across multiple payers) offer better continuity but introduce complexity in patient matching and linkage. Modern analytics platforms address this through sophisticated tokenization algorithms that maintain patient continuity across sources while preserving de-identification and GDPR compliance.
Third, representativeness varies. Commercial claims over-represent employed populations ages 18-64 and under-represent public insurance beneficiaries, uninsured, and certain demographic groups. Public health insurance claims capture specific populations but miss others. For accurate regional estimates, you need weighted combinations of commercial, public, and supplementary insurance claims to reflect true population demographics. Reputable data providers supply weighting factors and demographic adjustments to support this.
These challenges are manageable with proper methodology and realistic expectations about what claims data can and cannot tell you. The key is understanding the strengths and limitations, using appropriate analytical techniques (like inverse probability weighting to address selection bias), and supplementing with other data sources when needed. Best practices for real-world data studies emphasize combining data sources and applying rigorous methodological standards.
Navigating the Claims Data Landscape: What to Look For
The claims data market has evolved significantly, with dozens of providers offering overlapping but distinct capabilities. Understanding which combination of features aligns with your strategic priorities requires careful evaluation across several key dimensions.
Coverage and scale: Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater depth. The choice depends on whether you need broad market visibility or deep therapeutic area expertise. For rare disease analysis, you’ll need massive scale to achieve statistical power. For competitive intelligence in specific markets, focused coverage with rich detail may matter more.
Data recency and refresh frequency: The gap between service delivery and data availability varies dramatically. Some sources provide near real-time feeds (30-60 day lag), enabling tactical market monitoring. Others work with fully adjudicated claims (6-12 month lag), offering greater completeness but less timeliness. Your use case determines which trade-off makes sense—launch monitoring demands recency, while retrospective outcomes research can tolerate longer lags.
Analytical sophistication: Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Some providers deliver raw data requiring significant internal analytics resources. Others offer full-service analysis with domain expertise included. The choice depends on whether you need descriptive intelligence or forward-looking insights, and whether you have analytical capabilities in-house or need turnkey solutions.
Data integration and enrichment: Some sources combine claims with complementary data—lab results, specialty pharmacy records, provider characteristics, patient-reported outcomes—for richer patient profiles. This vertical integration creates analytical possibilities that pure claims data cannot support. Understanding what questions require these enriched datasets versus standard claims is critical to avoiding over-purchasing or under-delivering.
Cost models and flexibility: Pricing structures vary from subscription models (annual access to defined datasets) to project-based licensing (pay for specific analyses) to data-as-a-service platforms (usage-based pricing). Some providers require multi-year commitments; others offer month-to-month flexibility. The right model depends on your usage patterns, budget constraints, and organizational maturity with real-world data.
The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities. Understanding which data sources match specific use cases requires deep market knowledge that most companies lack internally.
The Future of Claims-Based Market Intelligence: AI, EHR Integration, and Synthetic Data
The real-world evidence landscape continues to evolve rapidly. Claims data providers are increasingly linking to electronic health records, adding clinical depth to administrative breadth. These linked datasets enable questions that pure claims cannot answer—like whether patients with specific biomarker levels respond better to certain therapies, or how patient-reported outcomes correlate with healthcare utilization and costs.
Artificial intelligence and machine learning are transforming what’s possible with claims analysis. Instead of manually defining patient cohorts using diagnostic algorithms, NLP models can identify complex phenotypes from unstructured data. Predictive models can forecast individual patient trajectories, identifying high-risk populations for intervention. Network analysis reveals hidden relationships between comorbidities, prescribing patterns, and outcomes that traditional statistical methods miss.
Synthetic data generation is particularly exciting for pharma market sizing applications. The FDA’s Sentinel Real World Evidence Data Enterprise demonstrates how privacy-preserving approaches enable broader access to healthcare data for research and regulatory purposes. Using generative adversarial networks (GANs) trained on real claims data, specialized providers can create synthetic patient populations that preserve statistical relationships and patterns while eliminating any linkage to actual individuals. This enables scenario modeling (“what if payer coverage restrictions change?”) without GDPR constraints on personal data processing.
For market sizing and forecasting, synthetic data allows stress-testing your assumptions. You can generate synthetic patient populations under different epidemiological scenarios, model various competitive entry situations, or simulate the impact of regulatory changes on utilization patterns. The synthetic data maintains the complex interdependencies present in real claims—like the relationship between age, comorbidities, and treatment choices—while allowing complete flexibility for “what-if” analysis.
Integrating Claims Intelligence Across the Pharmaceutical Value Chain
The most sophisticated pharma organizations are embedding claims-based intelligence throughout their commercial operations. This isn’t just about market sizing or forecasting—it’s about creating a real-world evidence capability that informs decisions across the entire value chain.
New product planning teams use claims data early in development to validate target product profiles, size opportunities, and prioritize indications. Instead of waiting for Phase III readouts to start commercial planning, they’re building evidence-based business cases during Phase II, using historical treatment patterns in the target indication to model various scenarios for efficacy, safety, and convenience attributes.
Clinical development teams are leveraging claims data for trial design optimization—identifying realistic inclusion criteria based on real-world patient characteristics, estimating screen failure rates, and selecting trial sites in geographies with high patient prevalence. Real-world data accelerates and guides drug development by informing trial design, enrollment strategies, and endpoint selection.
Market access teams build comprehensive value dossiers incorporating real-world treatment patterns, unmet needs analysis, and budget impact models grounded in actual utilization data. They’re prepared for payer objections with empirical evidence rather than assumptions.
Commercial analytics teams maintain ongoing surveillance of market dynamics—tracking competitor launches, monitoring policy changes, and identifying emerging trends in prescribing behavior. Instead of quarterly business reviews relying on lagging sales data, they’re conducting monthly (or even weekly) analyses of prescription trends, patient starts, and discontinuation patterns to inform tactical decisions.
This level of integration requires investment in data infrastructure, analytical talent, and cross-functional processes. But the ROI is substantial. Companies that excel at real-world evidence generate more accurate forecasts (reducing inventory and manufacturing risks), launch products more effectively (with better targeting and positioning), and secure favorable payer access (with compelling evidence). Frameworks for generating real-world evidence emphasize building organizational capabilities that span the full product lifecycle.
Strategic Implementation: Getting Started with Claims-Based Market Sizing
So you’re convinced that aggregated claims data should inform your market sizing and forecasting. What’s the practical path forward? A few recommendations based on what I’ve seen work (and not work) across dozens of implementations.
Define requirements before evaluating options. Start by documenting your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches between what you need and what you license.
Most companies skip this step and jump directly to evaluating providers, only to discover six months later that their data source doesn’t support their primary use case. Map your questions first, then find data that answers them.
Understand the landscape dimensions. The claims data market includes dozens of providers with overlapping but distinct capabilities. Coverage breadth, data recency, analytical sophistication, integration options, and cost models all vary significantly. Some excel at broad market surveillance; others specialize in deep therapeutic area expertise. Some provide raw data requiring internal analytics resources; others deliver turnkey insights with domain expertise included.
The gap between understanding what claims data can do and identifying which specific capabilities match your needs is substantial. This is where expert guidance becomes critical—advisors who understand both pharmaceutical commercialization and the evolving real-world evidence ecosystem can accelerate your path to value while avoiding common pitfalls.
Pilot before scaling. Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements. Pick a specific use case (upcoming launch, competitive intelligence need, market access challenge) where traditional methods have high uncertainty. Use the pilot to prove ROI, refine your processes, and build internal expertise.
Successful pilots typically run 3-6 months, involve cross-functional teams (commercial analytics, market access, brand marketing), and deliver tangible business impact (better forecast, successful payer negotiation, optimized launch strategy). Document lessons learned to inform your broader implementation.
Build analytical capabilities, not just data access. Raw claims data is complex—understanding how to define patient cohorts, handle missing data, account for selection bias, and interpret results requires specialized expertise. Either develop internal capabilities (hiring analysts with claims experience) or partner with analytics providers who deliver insights, not just data. Real-world evidence for regulatory decisions requires rigorous methodological approaches that go beyond basic data queries.
The most common failure mode in claims data initiatives is licensing expensive datasets without the analytical horsepower to extract value from them. Data without analysis is just expensive storage.
Leverage expert guidance for vendor selection. The claims data landscape is complex, with dozens of providers offering overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, and domain expertise matches your specific needs requires deep market knowledge. Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while avoiding costly mismatches.
Before evaluating specific data providers, expert consultants can help structure your requirements definition process to ensure you’re comparing options on the dimensions that actually matter for your use cases. This upfront investment in strategic clarity typically saves 6-12 months and hundreds of thousands of euros in avoided missteps.
Integrate with existing processes. Claims insights should inform—not replace—your current forecasting models, market research, and commercial planning. The most successful implementations embed claims analysis into established processes (quarterly business reviews, annual planning cycles, launch readiness assessments) rather than treating RWE as a separate workstream.
Establish governance for decision-making. Be explicit about how claims-based insights will influence strategic choices. If your epidemiology model says 100,000 patients but claims data suggests 60,000, which number drives your revenue forecast? Having clear decision criteria prevents analysis paralysis and ensures the investment in real-world data actually impacts outcomes.
Measuring ROI: The Business Case for Claims-Based Market Intelligence
The financial justification for investing in aggregated claims data capabilities is straightforward when you quantify the costs of inaccuracy. A pharmaceutical launch forecast that’s 30% too optimistic might lead to €40-80M in excess manufacturing costs, overstaffed sales forces, and disappointed investor expectations. A forecast that’s 30% too conservative costs even more in opportunity cost—underinvestment in manufacturing capacity, insufficient sales resources, and market share lost to competitors.
Claims-based market sizing typically improves forecast accuracy by 15-25 percentage points compared to traditional methods, according to industry benchmarks. For a product with €400M peak sales potential, that accuracy improvement could be worth €60-100M in avoided overproduction costs or captured revenue upside. The investment in data access and analytics capabilities (typically €160K-400K annually for mid-sized pharma) pays for itself many times over with just one major launch.
Beyond launch forecasting, the value compounds across multiple applications. Better market access negotiations (securing formulary placement without prior authorization might increase uptake by 20-30%), more efficient sales force deployment (targeting the right prescribers can improve rep productivity by 15-20%), and earlier identification of competitive threats (detecting market share erosion months sooner enables faster response) all contribute incremental value.
Organizations with mature RWE capabilities report 20-30% improvement in commercial planning accuracy, 15-20% reduction in go-to-market costs through better targeting, and 10-15% higher likelihood of securing favorable payer access. These aren’t marginal improvements—they’re competitive differentiators in an industry where accurate intelligence drives billion-euro decisions.
Making the Strategic Shift: From Assumptions to Evidence
The transformation from traditional pharma market sizing to claims-based approaches isn’t just methodological—it’s cultural. It requires accepting that your historical assumptions might be wrong, that epidemiology-based TAM calculations are starting points rather than answers, and that real-world complexity doesn’t fit neatly into spreadsheet models.
The uncomfortable reality is that many pharmaceutical forecasts fail not because the models are wrong, but because the inputs are based on idealized scenarios that don’t reflect clinical practice. Academic treatment algorithms aren’t always followed in community settings. Payer coverage assumptions don’t account for formulary restrictions and step-edits. Patient adherence estimates assume rational actors who take medications as prescribed. FDA’s framework for real-world evidence emphasizes using data from routine clinical practice to understand actual treatment effects and utilization patterns.
Aggregated insurance claims data forces you to confront these realities with evidence rather than assumptions. Yes, it’s messier than clean epidemiology models. Yes, it requires dealing with data quality issues and analytical complexity. But the alternative—making billion-euro decisions based on educated guesses—is riskier still.
The pharmaceutical companies winning in today’s market are those that have embraced this shift. They’re building real-world evidence capabilities as core competencies, not outsourced services. They’re integrating claims-based insights into strategic planning from clinical development through lifecycle management. And they’re generating more accurate forecasts, capturing greater market share, and delivering better returns to shareholders as a result.
For commercial analytics leaders, the question isn’t whether to incorporate claims data into market sizing—it’s how quickly you can build the capability before competitors gain an insurmountable evidence advantage. The data exists. The analytical tools are available. The methodology is proven. What’s required now is the organizational commitment to transform how pharmaceutical market opportunities are assessed and pursued.
Next Steps: Elevating Your Market Sizing Strategy with Expert Guidance
If you’re ready to move beyond traditional pharma market sizing approaches and leverage aggregated insurance claims data for more accurate opportunity assessment, the path forward starts with strategic clarity.
Begin by evaluating your current forecasting accuracy—where have your projections been most off-target? Those areas of high uncertainty are prime candidates for claims-based analysis to reduce risk and improve decision-making. Document the business impact of forecast errors: manufacturing overcapacity, missed market opportunities, suboptimal resource allocation. This quantification builds the business case for investing in better intelligence.
Understanding what types of claims data exist and what questions they can answer is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
Navigating this landscape requires expertise in both pharmaceutical commercialization and the complex vendor ecosystem. The gap between licensing claims data and extracting actionable intelligence is substantial. Expert advisors can help you:
- Define requirements that actually match your strategic priorities (not just what sounds good in theory)
- Understand which capabilities matter for your specific use cases versus generic feature lists
- Evaluate trade-offs between different data models, coverage approaches, and cost structures
- Avoid common implementation pitfalls that delay time-to-value by 6-12 months
- Build internal capabilities to maximize long-term ROI from your data investments
The pharmaceutical industry’s transformation toward evidence-based market sizing is well underway. Aggregated insurance claims data—billions of real-world transactions capturing actual prescribing, dispensing, and utilization patterns—provides the foundation for this shift. Companies that harness this intelligence effectively will make better strategic decisions, launch products more successfully, and capture market opportunities their competitors miss.
Ready to explore how claims-based market intelligence can transform your forecasting accuracy and commercial strategy?
Contact us to discuss your specific requirements and discover strategic approaches to real-world evidence that align with your business objectives. We’ll help you navigate the complex data landscape, avoid costly missteps, and build capabilities that deliver sustainable competitive advantage.
Sources & References
- Das P, Das A. Real-World Evidence: A Primer. Pharmaceut Med. 2023;37(1):25-36. https://pubmed.ncbi.nlm.nih.gov/36604368/
- Garrison LP Jr, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326-35. https://pubmed.ncbi.nlm.nih.gov/17888097/
- Chen Y, et al. Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective. Ther Innov Regul Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/39949314/
- Motheram R, Jiang Y. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacotherapy. 1999;19(7):819-28. https://pubmed.ncbi.nlm.nih.gov/10539118/
- Maro JC, et al. The FDA Sentinel Real World Evidence Data Enterprise (RWE-DE). Clin Pharmacol Ther. 2024. https://pubmed.ncbi.nlm.nih.gov/39385712/
- Cave A, et al. Real-world evidence to support regulatory decision making: New or expanded medical product indications. Pharmacoepidemiol Drug Saf. 2021;30(4):419-428. https://pubmed.ncbi.nlm.nih.gov/33675248/
- Eichler HG, et al. Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making. Clin Pharmacol Ther. 2016;100(6):639-648. https://pubmed.ncbi.nlm.nih.gov/27627027/
- Zhu R, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective. Clin Pharmacol Ther. 2023;114(3):564-578. https://pubmed.ncbi.nlm.nih.gov/37393555/
- Zhu R, et al. Integrating real-world data to accelerate and guide drug development: A clinical pharmacology perspective. Clin Pharmacol Ther. 2022;112(5):953-969. https://pubmed.ncbi.nlm.nih.gov/35912537/
- U.S. Food and Drug Administration. Real-World Evidence. FDA website (ongoing framework and guidance documents). https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- Baumfeld Andre E, et al. Trial designs using real-world data: The changing landscape of the regulatory approval process. Clin Pharmacol Ther. 2020;108(3):441-452. https://pubmed.ncbi.nlm.nih.gov/32378749/
- Berger ML, Sox H, Willke RJ, et al. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force. Value Health. 2017;20(8):1003-1008. https://pubmed.ncbi.nlm.nih.gov/28964485/
Related Resources:
